Company profile
Kali, Inc.
OTC: KALY · Healthcare · Drug Manufacturers - Specialty & Generic
#1075 of 1,422 Healthcare companies by revenue36th-percentile growth
EA Score
——FH —DQ —GM —SS 55
v0.1 · 5/100 weight · pillars only
↑ Altman-Z, workforce scale · ↓ balance-sheet leverage, market scale
Methodology →Revenue TTM
$106.0M
Rev growth YoY (TTM)
+28.1%
Net income (FY)
-$11.9k
Employees
171
as of 2026-08-28
Market cap
$101.8k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$65.3k$65.3k2018
Net income-$11.9k-$11.9k2018
Operating income-$11.9k-$11.9k2018
Total assets$41.5k$41.5k2018
Liabilities$588.1k$588.1k2018
Equity-$546.6k-$546.6k2018
Revenue trend
FY2009 – FY2018 · USD
FY09
FY10
FY11
FY12
FY15
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kali, Inc.’s revenue?
Kali, Inc. booked $65.3k in FY2018 revenue, contracting 3.4% year over year — slower than 64% of Healthcare companies we track, at a -18.2% net margin.
Peers · Healthcare
Neutra Corp.——Aquarius Surgical Technologies Inc.——Inovio Pharmaceuticals, Inc.37DConnect Biopharma Holdings Limited25DOxford Investments Holdings Inc.——Real Brands, Inc.——Neighbors
Dallas →Key facts
CEOFrederick Ferri
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersDallas, TX
ExchangeOTC: KALY
Employees171
IPO date2008-04-02
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.